In small-cell lung cancer (SCLC), miR-184 was shown to suppress tumour progression through the regulation of endothelial PAS domain protein 1 (EPAS1) and β-catenin, leading to decreased metastatic potential [25]. This evidence concerns the gene EPAS1 and small cell lung carcinoma.